Cancer: GSK and the King's College of London bet on artificial intelligence

GSK and King's College unite their strengths in the fight against cancer, with great artificial intelligence.The British laboratory and the London academic establishment announced a research partnership for five years aimed at using AI to better provide the impact of cancer treatments and personalize them.It is a question of understanding "what role play genetic factors" in the success of treatment, "how and why some patients react to certain treatments and what can be the cause of the progression of the disease in others", according to a press release from King's College.

Artificial intelligence will be used to carry out simulations on 3D models of tumors in 400 patients, who will help predict resistance to treatment or recurrence after therapies of immuno-oncology.This promising technique, which aims to exploit the patient's immune system to combat cancer, is only efficient in 20% of patients.Sometimes it works very well "and it makes cancer disappear" but "we would like it to work all the time", summarizes Doctor Kim Branson, world responsible for artificial intelligence and automatic learning at GSK, quoted by theGuardian.

>> A lire aussi - Cancer : des chiens renifleurs de tumeurs testés par l’Institut Curie

For the scientist, the research carried out with the King's College is like "playing failures against cancer", by developing the tools to predict the next blow and adapt the strategy in the face of the disease.The joint research pole will be formed by ten scientists from the King's College cancer center and ten of the artificial and experimental medicine units of GSK.

>> Notre service - Faites des économies en testant notre comparateur d’Assurances Santé

The GSK pharmaceutical giant (Glaxosmithkline), which had presented mixed results at the end of July, between the drop in the result and rectification of sales, hopes to launch a vaccine against the COVVI-19, developed by French Sanofi at the end of 2021, and startedAdvanced phase 3 tests for another Vaccini candidate with the South Korean SK Bioscience.

>> Achetez et vendez vos placements (actions, cryptomonnaies, or…) au bon moment grâce à Momentum, la newsletter de Capital sur l’analyse technique